Navigation Links
Inovio Pharmaceuticals Responds to Market Activity
Date:8/6/2013

BLUE BELL, Pa., Aug. 6, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that in view of the unusual market activity in the company's stock, the Exchange has contacted the company in accordance with its usual practice. The company stated that its policy is not to comment on unusual market activity.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused precancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis C virus. Partners and collaborators include the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
2. Inovio Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Inovio Pharmaceuticals to Present at SPI 2012
4. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
5. Inovio Pharmaceuticals to Present at JMP Investor Conference
6. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
7. Inovio Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
8. Inovio Pharmaceuticals Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. Inovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
10. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
11. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 /CNW/ - ... is being recalled after Health Canada tests confirmed it ... health risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health ... recalling the product from retail stores across ... building purposes, including for weight loss and increased energy. ...
(Date:12/24/2014)...  Novastem, a leader in regenerative medicine, announces ... study for ischemic stroke at Clinica Santa Clarita. ... account for 87 percent of all stroke cases. ... study, entitled "Internal Research Protocol in Combination Therapy ... and Intrathecal Administration of Neural Stem Cells in ...
(Date:12/24/2014)... , Dec. 24, 2014  Actavis plc ... the Company has received a complete response letter ... for its New Drug Application (NDA) for the ... the treatment of hypertension.   Photo - ... are disappointed in the receipt of a complete ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4
... Oct. 27 According to Millennium Research Group ... intelligence, the European arthroscope market generated over $30 ... over 2009 due to decreasing scope prices and ... Due to unfavorable economic conditions, manufacturers are ...
... today announced that it has received approval from the ... (US 7,815,929) regarding a method for the preparation, storage ... very nature, the process of compounding suppositories is cumbersome, ... Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. ...
Cached Medicine Technology:Despite Rising Procedure Volumes, the $30 Million European Arthroscope Market Experienced Nominal Growth in 2010 2Despite Rising Procedure Volumes, the $30 Million European Arthroscope Market Experienced Nominal Growth in 2010 3CutisPharma Announces Issuance of an Additional Patent for Suppository Compounding 2
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
(Date:12/25/2014)... LunaDress.co.uk has updated its blog to provide professional shopping tips on ... models at LunaDress.co.uk come with big discounts, up to 80 percent ... turn out to be a most exciting memory and can show ... surprise to a wedding. On the updated fashion blog, ladies can ... a big day . , Going out with friends to a ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Overeating is common during the holidays, ... moderation, an expert says. "Don,t arrive at a party ... you know you,ll be attending a party, but deprivation leads ... dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., said ... healthy during the day and even to have a snack ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the experience of ... has introduced its new collection of 2015 prom dresses, ... new prom outfits are guaranteed to contain the perfect ... specially designed for 2015. Anyone who wants to buy ... website before Jan. 26, 2015, the deadline of the ...
(Date:12/25/2014)... Viejo, California (PRWEB) December 25, 2014 ... release of ProFire 5k. A fully customizable business presentation ... . , “Adding the ProFire 5k business tool, users ... Said Christina Austin, CEO of Pixel Film Studios. “ProFire ... look and style to add professionalism to a presentation” ...
Breaking Medicine News(10 mins):Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... Dr. Lawyer will lead clinical efforts of the ... KePRO, a national medical,management firm, appointed Lenaye ... Dr. Lawyer will oversee all clinical aspects of ... Harrisburg,office., "Dr. Lawyer has practiced her entire ...
... the Northeast region with more hires,planned throughout the ... Aug. 28 The Pennsylvania,Patient Safety Authority has ... to help healthcare facilities that report to the,Pennsylvania ... Pennsylvania citizens., "Last year in focus groups ...
... 67%, but patients and doctors say drug is hard to ... percent of patients with atrial fibrillation, a known risk factor ... anti-clotting drug warfarin, a new study found. , Among those ... prevent a stroke. And an additional 25 percent were taking ...
... growing professional and consumer markets in China. , ... ... international venture capital firm, today announced that together with Mustang Ventures, ... of financing for Profex.Inc. Trident Capital & Mustang Ventures jointly invested ...
... HAYWARD, Calif., Aug. 28 Guava Technologies, Inc.,announced ... Group to,provide drug discovery researchers with an automated ... key component of a larger,strategic initiative by Guava ... voiced need for sophisticated cell analysis technology to,support ...
... increased plaque , , THURSDAY, Aug. 28 (HealthDay News) -- A ... in the brain that is thought to play a key ... the protein, known as amyloid beta, was directly linked to ... When brain cell communication increased, so did amyloid beta. When ...
Cached Medicine News:Health News:Lenaye Lawyer, MD, FACOG, Named KePRO Medical Director 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3Health News:Most Patients With Irregular Heartbeat Take Inadequate Blood Thinner Dose 2Health News:Most Patients With Irregular Heartbeat Take Inadequate Blood Thinner Dose 3Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 2Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 3Health News:San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research 2Health News:San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research 3Health News:Scientists Track Hourly Changes in Alzheimer's Protein 2
... D-Stat Flowable Hemostat has a ... topical application, such as vascular access ... It is also used as an ... of tissue tracts of femoral access ...
... Hemostasis Pad is intended for use in the ... sites and percutaneous catheters or tubes. The Pad ... powerful hemostatic agent. Chitosan gel is twice as ... which it is derived. When placed over the ...
... The EVS is engineered to close ... The ergonomic stapler with a simple ... operator. A deliver sheath gently ... maintains control of the site before, ...
The Prostar XL 8 is a suture mediated closure system. It can be used with 8F sheath. It has two 3-0 braided polyester sutures and also has the safety of guidewire....
Medicine Products: